

EGF Theramed Files Amended and Restated Annual MD&A for the Year 2019 and Interim MD&A for Q3 2020

Vancouver, B.C., September 11, 2020 – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the "**Company**) announces that it has filed amended and restated management's discussion and analysis for the fiscal year ended June 30, 2019 and for the nine month period ended March 31, 2020 (together, the "Amended MD&As"). The Amended MD&As have been revised to correct typographical errors and to address comments received from British Columbia Securities Commission staff to help improve the Company's disclosure.

Among other changes, the Amended MD&As have been revised to:

- provide additional information on its overall performance and business development;
- clarify and provide additional disclosure regarding EGF's closed and terminated acquisitions, property and equipment status and the status of the development of its mobile app;
- clarify and provide additional disclosure regarding the results of operations, annual results, and quarterly results;
- clarify related party transactions; and
- provide additional information on its financial and capital risk management.

The amended information relates only to the management's discussion and analysis for the relevant periods, and no changes were made to the financial statements for the corresponding periods.

The Amended MD&As are available under the Company's profile on SEDAR at www.sedar.com.

FOR MORE INFORMATION PLEASE CONTACT:

EGF THERAMED HEALTH CORP.

Doug McFaul

Email: dmcfaul@emprisecapital.com

Telephone: (778) 331 8505

Website: http://www.theramedhealthcorp.com

CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation

US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news Frankfurt Borse: https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp